%0 Journal Article
%T Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes
%A Jianhua Zhang
%A Jing Jia
%A Junhui Xie
%A Mengni Li
%A Puhan Lu
%A Shiying Shao
%A Shujun Zhang
%A Wentao He
%A Xi Chen
%A Xuefeng Yu
%A Yan Yang
%A Yongping Xu
%A Zeqing Zhang
%J Archive of "Cardiovascular Diabetology".
%D 2017
%R 10.1186/s12933-017-0512-z
%X Incretin-based agents, including dipeptidyl peptidase-4 inhibitors (DPP-4Is) and glucagon-like peptide-1 agonists (GLP-1As), work via GLP-1 receptor for hyperglycemic control directly or indirectly, but have different effect on cardiovascular (CV) outcomes. The present study is to evaluate and compare effects of incretin-based agents on CV and pancreatic outcomes in patients with type 2 diabetes mellitus (T2DM) and high CV risk
%K Glucagon-like peptide-1 agonists
%K Dipeptidyl peptidase-4 inhibitors
%K Type 2 diabetes mellitus
%K Cardiovascular outcomes
%K Acute pancreatitis
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333444/